EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia

Steven P Treon iD, Shayna Sarosiek, Jorge J Castillo iD

Blood · 2024

DOI: 10.1182/blood.2022017235 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Blood, 2024. Verfasst von Steven P Treon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors, Waldenstrom Macroglobulinemia. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in MYD88 (95%-97%) and CXCR4 (30%-40%) are common in Waldenström macroglobulinemia (WM). TP53 is altered in 20% to 30% of patients with WM, particularly those previously treated. Mutated MYD88 activates hematopoietic cell kinase that drives Bruton tyrosine kinase (BTK) prosurvival signaling. Both nonsense and frameshift CXCR4 mutations occur in WM. Nonsense variants show greater resistance to BTK inhibitors. Covalent BTK inhibitors (cBTKi) produce major responses in 70% to 80% of patients with WM. MYD88 and CXCR4 mutation status can affect time to major response, depth of response, and/or progression-free survival (PFS) in patients with WM treated with cBTKi. The cBTKi zanubrutinib shows greater response activity and/or improved PFS in patients with WM with wild-type MYD88, mutated CXCR4, or altered TP53. Risks for adverse events, including atrial fibrillation, bleeding diathesis, and neutropenia can differ based on which BTKi is used in WM. Intolerance is also common with cBTKi, and dose reduction or switchover to another cBTKi can be considered. For patients with acquired resistance to cBTKis, newer options include pirtobrutinib or venetoclax. Combinations of BTKis with chemoimmunotherapy, CXCR4, and BCL2 antagonists are discussed. Algorithms for positioning BTKis in treatment naïve or previously treated patients with WM, based on genomics, disease characteristics, and comorbidities, are presented.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsWaldenstrom MacroglobulinemiaAdultAgedFemaleHumansMaleMiddle AgedGenomicsMutationMyeloid Differentiation Factor 88PiperidinesPyrazolesPyrimidinesReceptors, CXCR4

Substanzen

Agammaglobulinaemia Tyrosine KinaseBTK protein, humanCXCR4 protein, humanMYD88 protein, humanMyeloid Differentiation Factor 88PiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesReceptors, CXCR4

Autor:innen und Institutionen

  • Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
  • Harvard Medical School, Boston, MA.

ORCID-Profile: Steven P Treon, Jorge J Castillo

Förderung

  • NCI NIH HHS

Zitieren

APA

Treon, S. P., Sarosiek, S., & Castillo, J. J. (2024). How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia. Blood. https://doi.org/10.1182/blood.2022017235

Vancouver

Treon SP, Sarosiek S, Castillo JJ. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia. Blood. 2024. doi:10.1182/blood.2022017235

BibTeX
@article{Treon2024,
  author = {Treon, Steven P and Sarosiek, Shayna and Castillo, Jorge J},
  title = {How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia},
  journal = {Blood},
  year = {2024},
  doi = {10.1182/blood.2022017235}
}
Kostenlos starten →